

---

UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE

DEPARTEMENT DE MEDECINE

DIVISION DE PHYSIOPATHOLOGIE CLINIQUE

---

**A COMPARATIVE STUDY OF REACTIVE HYPEREMIA  
IN HUMAN FOREARM SKIN AND MUSCLE**

THESE

préparée sous la direction du Professeur associé François Feihl  
et présentée à la Faculté de biologie et de médecine de l'Université de Lausanne  
pour l'obtention du grade de

DOCTEUR EN MEDECINE

par

Guérolé ADDOR

WG  
106  
Add

Médecin diplômé de la Confédération Suisse  
Originaire de Vuiteboeuf (Vaud)

B.M.T.E 3518

Lausanne  
2009

Bibliothèque Universitaire  
de Médecine / BIUM  
CHUV-BH08 - Bugnon 46  
CH-1011 Lausanne

R0051 88729

# Imprimatur

*Vu le rapport présenté par le jury d'examen, composé de*

*Directeur de thèse Monsieur le Professeur associé François Feihl*

*Co-Directeur de thèse*

*Expert Madame le Docteur Lucia Mazzolai*

*Directrice de l'Ecole doctorale Madame le Professeur Stephanie Clarke*

*la Commission MD de l'Ecole doctorale autorise l'impression de la thèse de*

***Monsieur Guénolé-Lucien Addor***

*intitulée*

***A comparative study of reactive hyperemia in human forearm  
skin and muscle***

*Lausanne, le 26 mai 2009*

*pour Le Doyen  
de la Faculté de Biologie et de Médecine*



*Madame le Professeur Stephanie Clarke  
Directrice de l'Ecole doctorale*

## RAPPORT DE SYNTHÈSE

L'hyperémie réactive dans la microcirculation musculature et cutanée de l'avant-bras permet d'évaluer l'atteinte vasculaire dans les maladies cardiovasculaires. Cette méthode permet d'obtenir un reflet de la progression de l'atteinte vasculaire, de traquer la progression de la maladie ainsi que le risque cardio-vasculaires. Elle est en étude également pour tester l'efficacité d'une intervention thérapeutique. L'hyperémie réactive est dépendante d'une dilatation post ischémique par diminution des résistances artériolaires. Au niveau des membres, l'ischémie peut-être débutée et interrompue très facilement par une manchette à pression gonflée au-dessus de la pression systolique suivie quelques minutes plus tard de son dégonflement. Les mesures de flux sanguin musculaire et cutané au niveau d'un membre sont faciles à réaliser chez l'homme, tout particulièrement au niveau de l'avant-bras.

Pour l'instant aucune étude utilisant cette approche ne spécifiait quel avant-bras était utilisé. Il est cependant concevable que la réponse varie selon que l'on teste le bras dominant ou non-dominant. Il paraît donc important de clarifier ce point. Le premier but de l'étude consiste donc à investiguer une éventuelle différence entre le bras dominant et le bras non-dominant d'un sujet lors de tests de l'hyperémie réactive dans le muscle et la peau.

Il est connu que l'hyperémie réactive au niveau musculaire peut-être diminuée par les médicaments anti-inflammatoires non stéroïdiens (AINS), indiquant une implication partielle des métabolites de la cyclo-oxygénase. L'influence des AINS sur la réponse cutanée est moins clairement établie. Ainsi, le second but de cette étude est de comparer l'effet de l'inhibition de la cyclo-oxygénase sur l'hyperémie réactive musculaire et cutanée chez des sujets sains.

Le collectif de patients consiste en 23 sujets masculins volontaires, en bonne santé, non fumeurs, de 18 à 30 ans. Aucuns antécédents médicaux ne sont connus et aucune médication n'est prise durant la période de l'étude. Tous les sujets ont donné leur consentement par écrit. Le flux sanguin musculaire de l'avant-bras est mesuré au moyen d'une pléthysmographie par occlusion veineuse, et le flux cutané l'est par imagerie laser Doppler.

Les expériences ont lieu entre 16 et 18 h dans une chambre calme à température constante (23-24°C) chez un sujet couché. Les participants n'ont pas consommé d'AINS durant la semaine précédente ni bu de café dans les 12 h précédant l'expérience.

Les mesures sont effectuées en triplicat au niveau musculaire puis cutané ou inversement selon un ordre aléatoire. Suite à une occlusion artérielle l'étude du flux se fait sur 3 min et 5 min de récupération sont prises entre 2 mesures.

L'expérience 1 consiste à tester un possible effet systématique de la latéralisation du bras dominant ou non sur la réponse à l'hyperémie réactive dans la peau et le muscle de l'avant-bras. 16 sujets sont étudiés à 2 reprises, espacées de 1 à 3 jours. A la première visite, l'hyperémie musculaire est étudiée dans un avant-bras, la réaction cutanée dans l'autre et inversement lors de la deuxième visite. Une précaution est observée afin de mesurer le flux sanguin cutané à la même distance du poignet dans les 2 avant-bras.

L'expérience 2 est développée pour évaluer l'impact d'une inhibition des cyclo-oxygénases. Sept sujets sont considérés à 2 occasions espacées de 7 à 10 j. L'étude s'effectue uniquement au niveau de l'avant-bras dominant. Le site cutané au niveau du poignet est marqué lors de la première visite afin d'utiliser le même site de mesure lors de la seconde visite. Le sujet ingère 1,8 g d'Aspegic (équivalent à 1 g d'acide acétylsalicylique) dissout dans 125 ml de jus d'orange ou le jus d'orange seul lors de l'autre visite selon un ordre randomisé. Les mesures sont débutées 2 h après la prise.

Les résultats sont résumés selon 1) le pic d'augmentation du flux sanguin au-dessus de la valeur de base mesurée avant l'occlusion artérielle et 2) la durée de l'hyperémie calculée depuis le relâchement de l'occlusion artérielle jusqu'à une valeur d'augmentation du flux au-dessus de la ligne de base inférieure à 25% de la valeur au pic. La valeur du  $p$  est fixée à 0.05. Les données sont résumées selon une valeur moyenne  $\pm$  dérivation standard.

L'étude des résultats ayant rapport au premier but de l'étude démontre l'absence de différence systématique dans l'avant-bras dominant ou non-dominant lors d'une mesure de l'hyperémie réactive musculaire ou cutanée.

Les résultats concernant le deuxième but de l'étude sont les suivants ; cette dose d'acétylsalicylate orale est suffisante pour diminuer la durée de la réponse hyperémique dans la peau mais pas pour réduire son pic maximal.

Au niveau musculaire, le pic est statistiquement diminué mais pas la durée de la réponse. Cependant, la pléthysmographie pour une question purement pratique, ne permet pas de capturer les premières secondes de l'hyperémie et pourrait donc manquer le pic maximal, sachant que nos données considèrent le pic que 6 à 9 s après le dégonflement de la manchette à pression. Ainsi, nous ne pouvons pas prétendre évaluer l'impact d'un AINS sur le flux sanguin musculaire maximal post ischémique par la pléthysmographie. Ceci nécessite une autre méthodologie pour mesurer le flux sanguin musculaire.

En résumé, nos données montrent que l'hyperémie réactive cutanée et musculaire ne diffère pas systématiquement entre le côté dominant ou non-dominant mais peuvent toutes 2 être diminuées par la prise d'acide acétylsalicylique. Ainsi ces méthodes d'évaluation des maladies cardiovasculaires peuvent être utilisées sans tenir compte du côté étudié mais l'influence des AINS est à prendre en considération. Toutefois cette dernière restriction ne s'applique pas au pic de réponse au niveau cutané.

# A Comparative Study of Reactive Hyperemia in Human Forearm Skin and Muscle

G. ADDOR<sup>1</sup>, A. DELACHAUX<sup>1</sup>, B. DISCHL<sup>1</sup>, D. HAYOZ<sup>2</sup>, L. LIAUDET<sup>3</sup>, B. WAEBER<sup>1</sup>, F. FEIHL<sup>1</sup>

<sup>1</sup>Division de Physiopathologie Clinique, Département de Médecine, <sup>2</sup>Service d'Angiologie, Département de Médecine and <sup>3</sup>Service de Médecine Intensive Adulte, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Received February 22, 2007

Accepted July 11, 2007

On-line October 11, 2007

## Summary

Reactive hyperemia (RH) in forearm muscle or skin microcirculation has been considered as a surrogate endpoint in clinical studies of cardiovascular disease. We evaluated two potential confounders that might limit such use of RH, namely laterality of measurement and intake of non-steroidal anti-inflammatory drugs (NSAIDS). Twenty-three young non-smoking healthy adults were enrolled. In Experiment 1 (n=16), the RH elicited by 3 min of ischemia was recorded in the muscle (strain gauge plethysmography, hand excluded) and skin (laser Doppler imaging) of both forearms. In Experiment 2 (n=7), RH was determined in the dominant forearm only, one hour following oral acetylsalicylic acid (1 g) or placebo. In Experiment 1, peak RH was identical in both forearms, and so were the corresponding durations of responses. RH lasted significantly less in muscle than in skin (p=0.003), a hitherto unrecognized fact. In the skin, acetylsalicylate reduced duration (43 vs. 57.4 s for placebo, p=0.03), without affecting the peak response. In muscle, duration tended to decrease with acetylsalicylate (21.4 vs. 26.0 s with placebo, p=0.06) and the peak increase in blood flow was blunted (27.2 vs. 32.4 ml/min/100 ml tissue with placebo, p=0.003). We conclude that, when using RH as a surrogate endpoint in studies of cardiovascular disease, a confounding by laterality of measurement need not be feared, but NSAIDS may have an influence, although perhaps not on the peak response in the skin.

## Key words

Vasodilation • Ischemia • Laser Doppler • Strain gauge plethysmography • Surrogate endpoint • Acetylsalicylate

## Corresponding author

François Feihl, Division of Clinical Pathophysiology, Lausanne University Hospital, PPA, BH10-701, CHUV, 1011 Lausanne, Switzerland. E-mail: Francois.Feihl@chuv.ch

## Introduction

Cardiovascular diseases are presently a major cause of morbidity and death worldwide. Intervention trials focusing on so-called "hard" end-points, i.e. events such as an occurrence of stroke, acute myocardial infarction, newly diagnosed heart failure, or death are usually both extremely expensive and technically complicated, requiring the inclusion of huge number of patients observed over several years in order to achieve sufficient power (Williams 2005). In addition, it has been pointed out that the aforementioned endpoints lack both specificity and sensitivity when evaluating the efficacy of potential new therapies or prevention strategies (Cohn 2004). For these reasons, a substantial effort has been directed at identifying surrogate endpoints for cardiovascular disease, i.e. markers that would be linked to underlying pathophysiological events, thus reflecting disease progression and obviating the need to wait for the occurrence of clinical events, at least in trials designed to test for the efficacy of an intervention.

Numerous surrogate endpoints have been proposed (Cohn *et al.* 2004, Mancini *et al.* 2004). For some invasive maneuvers are required, examples being the assessment of endothelial function from the vasodilation induced by an intra-arterial infusion of acetylcholine into the coronary or forearm circulation. Other surrogate endpoints are accessible non-invasively, such as flow-induced vasodilation of the brachial artery, or the carotid intima-media thickness ratio, which can both be determined with ultrasonic techniques. The

assessment of such non-invasively available endpoints requires considerable technical skills and/or shows substantial operator dependence, which constitutes an obstacle to large scale usage in trials or epidemiological studies. One exception is the evaluation of reactive hyperemia, i.e. the transient increase of blood flow above resting level observed after a short period of ischemia. Reactive hyperemia is dependent on the post-ischemic dilation of resistance arterioles. It is easily assessed in limbs, where ischemia can be started and terminated very simply by the inflation above systolic pressure, followed a few minutes later by deflation of a proximally placed pneumatic cuff. In these conditions, limb blood flow can be measured serially with strain gauge plethysmography, a method that in the forearm essentially reflects perfusion to skeletal muscle if care is taken to exclude the hand circulation in the course of assessment. Alternatively, microvascular skin blood flow can be recorded at a site distal to the cuff with laser Doppler flowmetry. Both strain gauge plethysmography and laser Doppler flowmetry are noninvasive, do not require a high level of training, and produce results essentially independent of the operator.

Whether assessed in forearm muscle (Sanada *et al.* 2002) or skin (Binggeli *et al.* 2003), reactive hyperemia was diminished in hypercholesterolemic subjects in comparison with normocholesterolemic ones. In 862 healthy women, Vuilleumier *et al.* (2002) found that the peak reactive hyperemic response in forearm skin was negatively correlated with the Framingham risk score. The duration of reactive hyperemia in forearm muscle decreased with the accumulation of risk factors in 449 subjects devoid of overt cardiovascular disease (Ishibashi *et al.* 2006). Forearm skin reactive hyperemia was blunted in type 1 and type 2 diabetics (Tur *et al.* 1991, Skrha *et al.* 2001), and so was its muscle counterpart in patients with heart failure (Hirooka *et al.* 1994) or in those who later developed restenosis following coronary angioplasty (Wu *et al.* 2000). Taken together, these observations support reactive hyperemia as a potentially useful marker of cardiovascular disease.

It is noteworthy that none of these clinical studies specified which forearm was used for assessing reactive hyperemia. At least in the muscular vascular bed, it is conceivable that the response could differ between the dominant and non-dominant arm. In 16 young healthy adults, Carlsson *et al.* (1987) found that muscular reactive hyperemia was on the average 20 % greater in the right than in the left forearm, but did not report whether any of

these subjects were left-handed. We were unable to locate any other study concerning the effects of laterality on forearm reactive hyperemia. It would be important to clear this methodological point if these vascular responses are to be used for investigational purposes. The first aim of the present study was therefore to investigate possible systematic differences between the dominant and non dominant forearm regarding reactive hyperemia in muscle and skin.

It is known that forearm muscle reactive hyperemia in humans can be blunted by non steroidal antiinflammatory drugs (NSAID) (Kilbom and Wennmalm 1976, Carlsson and Wennmalm 1983, Carlsson *et al.* 1987, Engelke *et al.* 1996), indicating a partial dependence on metabolites of the cyclo-oxygenase (COX) pathway. Whether prostanoids also act as mediators of this response in human skin is less clear in view of contradictory reports indicating either no effect (Moppett *et al.* 2003, Dalle-Ave *et al.* 2004) or some inhibition by NSAIDs (Carlsson *et al.* 1983, Bisgaard *et al.* 1986, Binggeli *et al.* 2003). This point is relevant to the use of reactive hyperemia as a surrogate endpoint for cardiovascular disease, in view of the widespread intake of NSAIDs in the general population (Andersson *et al.* 1999). Therefore, our second aim was to compare the effects of COX inhibition on forearm skin and muscle reactive hyperemia in healthy humans.

## Methods

### Subjects

A total of 23 lean male non-smoking volunteers aged 18-30 years were studied. Medical history was unremarkable in all, and none had been on any medication for the month preceding the investigation. Approval was obtained from our Institutional Review Board for Human Experimentation. All subjects gave their informed consent in written.

### Reactive hyperemia

A standard size pneumatic cuff was placed around the upper arm. Following baseline measurement of either skin or muscle blood flow in the corresponding forearm (see below for details of blood flow measurements), the upper arm cuff was inflated for 3 min to a pressure of 200 mm Hg (i.e. largely above systolic), in order to achieve occlusion of arterial inflow, and then deflated, by means of an EC20 rapid cuff inflator (Hokanson, Bellevue, WA, USA).

### *Measurement of forearm muscle blood flow*

The hand was excluded from the circulation by inflation above systolic pressure of a pediatric blood pressure cuff placed around the wrist. In such conditions, the arterial inflow to the forearm, as provided by venous occlusion strain gauge plethysmography, essentially represents blood flow to skeletal muscle. Venous occlusion was accomplished by means of the upper arm cuff, again inflated with the EC20 inflator, to a pressure of 40 mmHg for 6 s. The rate of increase in forearm volume in the course of venous occlusion was measured with a mercury strain gauge (Hokanson No. 20 or 22, depending on forearm size) connected to a TL100 plethysmograph (Hokanson). The generated analog signal was digitized with a Powerlab ML880 system (ADInstruments, Spechbach, Germany), visualized online for quality control (checking in particular for the presence of cardiogenic oscillations, which are required for data validity) and stored on computer disk for later processing. The Powerlab system also controlled the rapid cuff inflator, such that venous occlusions took place at regular 12-s intervals, starting 6 s after release of arterial occlusion. Blood flow was expressed in ml per minute and per 100 ml of tissue volume.

### *Measurement of forearm skin blood flow*

A laser Doppler Imager (LDI, Moor Instruments, Axminster, UK) was used to measure dermal blood flow within a 0.5x2 cm area of distal forearm skin (at approximately 5 cm from the wrist), as previously described in this laboratory (Kubli *et al.* 2000, Pellaton *et al.* 2002, Boegli *et al.* 2003). Flow measurements, each lasting 2 s, were repeated at regular 5-s intervals, starting immediately after release of arterial occlusion. Erythrocyte flux was expressed in Perfusion Units (PU), as usual with laser Doppler flowmetry.

### *Protocols*

The study was approved by the Institutional Review Board on Human Experimentation at the University of Lausanne. The participants gave their informed consent in written. They were asked to not take any antiinflammatory drugs in the week, and not to drink any coffee in the 12 h, which preceded the study. All experiments took place between 4 and 6 p.m., in a quiet, temperature-controlled room (23-24 °C), with the subject lying supine on a hospital bed.

### *Timing of measurements*

In all experiments, measurements of post-

occlusive blood flow were carried out in triplicate in skin, and then in triplicate in muscle, or in the reversed order according to a randomization scheme. It was not feasible to simultaneously explore both territories, because small forearm movements generated by the repeated cuff inflations inherent to plethysmography would have interfered with laser Doppler flowmetry. Allowing for 5 min of restored blood flow before the next arterial occlusion (which lasted 3 min as stated above), one triplicate recording of reactive hyperemia in one territory took 25 min.


### *Experiment 1*

This experiment was designed to test for a possible systematic effect of laterality on the reactive hyperemic response of forearm skin and muscle. Sixteen subjects were studied on two occasions 1 to 3 days apart. On the first visit, muscle reactive hyperemia was recorded in one forearm, and skin muscle hyperemia in the other. Laterality of measurements was reversed on the second visit. Care was taken to assess skin blood flow at the same distance from the wrist on both forearms.

### *Experiment 2*

This experiment was designed to evaluate the impact COX blockade on the reactive hyperemic response of forearm skin and muscle. Seven subjects were studied on two occasions 7 to 10 days apart. Reactive hyperemia was assessed in the dominant forearm only. On the first visit, the exact location of the site for skin blood flow measurement was marked on a transparent acetate film, together with the anatomical outline of the forearm, taking care to precisely reproduce the position of the distal skin fold marking the limit of the wrist. In this way, the same skin site could be probed on the second visit, thus removing one source of experimental variation.

The subject ingested 1.8 g of lysine acetylsalicylate (Aspegic®, equivalent to 1 g of acetylsalicylate) dissolved in 125 ml orange juice on one visit, and the same volume of orange juice alone on the other visit, in a randomized order. This dose of acetylsalicylate has been shown in our laboratory to block COX-dependent dermal microvascular vascular responses, with an efficiency maintained between 30 min and 2 h following administration (Golay *et al.* 2004). Skin and muscle reactive hyperemia were determined in triplicate within the second hour after ingestion.




**Fig. 1.** Time course of reactive hyperemia induced by 3 min of ischemia (dashed vertical lines) in skin and muscle, evaluated in the dominant and non-dominant arm of 16 healthy subjects. Data are means  $\pm$  S.D.

The time course of each reactive hyperemic response was summarized as 1) the peak increase of blood flow above the baseline value measured immediately before arterial occlusion, and 2) the duration of hyperemia, calculated from the release of arterial occlusion to the time when the increase of blood flow above baseline became less than 25% of its peak value. No systematic effect the order of measurement within one series of triplicate was apparent from the data. Therefore, values of parameters derived from individual reactive hyperemia were averaged within triplicates. Then, statistical comparisons between responses obtained from the dominant and non-dominant arm (Experiment 1) or recorded after placebo and acetylsalicylate ingestion (Experiment 2) were carried out with paired t-tests, at an alpha level of 0.05. Data were summarized as mean  $\pm$  SD.

## Results

### Experiment 1

The mean time courses of skin and muscle blood flow following 3 min of ischemia are shown in Figure 1. There were no differences between the dominant and non-dominant forearm. A striking feature was the much longer duration of reactive hyperemia in the skin as compared to the response in muscle. These visual




**Fig. 2.** Summary measures of reactive hyperemia induced by 3 min of ischemia in skin and muscle, evaluated in the dominant and non-dominant arm of 16 healthy subjects. §§  $p < 0.01$  duration in skin vs. duration in muscle. Data are means  $\pm$  S.D.

impressions conveyed by Figure 1 are quantified in Figure 2. The peak responses were practically identical in both forearms (muscle  $27.8 \pm 2.2$  and  $28.3 \pm 6.0$  ml/min/100 ml tissue  $p = 0.75$ , skin  $272 \pm 50$  and  $249 \pm 55$  perfusion units  $p = 0.14$ , on respectively the dominant and non-dominant sides), and so were the corresponding durations (muscle  $24.8 \pm 7.7$  and  $24.2 \pm 5.7$  s,  $p = 0.75$ , skin  $54.1 \pm 22.4$  and  $51.8 \pm 23.1$  s,  $p = 0.66$ ). The difference in duration between reactive hyperemia in muscle and skin was highly significant ( $p = 0.003$ ).

### Experiment 2

Figure 3 depicts the mean time courses of reactive hyperemia in skin and muscle of the dominant forearm, following the ingestion of either 1 g acetylsalicylate or placebo, and the corresponding quantitations are shown in Figure 4. In the skin, COX blockade resulted in a somewhat shorter duration of hyperemia (acetylsalicylate 43.2 vs. placebo 57.4 s,  $p = 0.03$ ), without affecting the peak response (acetylsalicylate 286 vs. placebo 295 perfusion units,  $p = 0.75$ ). In forearm muscle, duration tended to decrease with acetylsalicylate (21.4 vs. 26.0 s with placebo,  $p = 0.06$ ) and the peak increase in blood flow was significantly blunted ( $27.2$  vs.  $32.4$  ml/min/100 ml tissue




**Fig. 3.** Time course of reactive hyperemia induced by 3 min of ischemia (dashed vertical lines) in skin and muscle, evaluated in the dominant arm of 7 healthy subjects, following the ingestion of either placebo or acetylsalicylate (1g). Data are means  $\pm$  S.D.

with placebo,  $p=0.003$ ). Again, the difference in duration between reactive hyperemia in muscle and skin was significant ( $p=0.01$ ), although not affected by acetylsalicylate.

## Discussion

As a transient response of distal vascular beds upon relief of temporary ischemia, reactive hyperemia depends on multiple mechanisms. Metabolic factors, in the form of local accumulation and subsequent washout of vasodilator metabolites such as carbon dioxide, ADP or adenosine, are in all likelihood important, with supporting evidence ranging from response prolongation with increasing duration of ischemia to its partial inhibition by pharmacologic blockade of adenosine receptors (Carlsson *et al.* 1987). However, there is also strong experimental evidence for the importance of mechanical factors, acting in large part, although not exclusively via the endothelial release of vasodilator mediators (Koller and Kalley 1990b). As recently described in details by Koller and Bagi (2002), such factors could include deformation of endothelial cells when arterioles collapse in the course of flow interruption, as well as their stimulation by stretch and shear stress when reperfusion occurs. Thus, reactive hyperemia might serve as a clinical index of endothelial function, an attractive concept because this vascular



**Fig. 4.** Summary measures of reactive hyperemia induced by 3 min of ischemia in skin and muscle, evaluated in the dominant arm of 7 healthy subjects, following the ingestion of either placebo or acetylsalicylate (1 g). \*  $p<0.05$ , \*\*  $p<0.01$  acetylsalicylate vs. placebo. §§  $p<0.01$  duration in skin vs. duration in muscle. Data are means  $\pm$  S.D.

response can be easily recorded non invasively with the methods used in the present paper. In accordance with this expectation, a tight correlation was found in a mixed population of hypertensive and healthy adults between peak reactive hyperemia in forearm muscle (measured with plethysmography) and the gold standard of endothelial function in humans, namely the response of forearm blood flow to the intrarterial infusion of acetylcholine) (Higashi *et al.* 2001). Considering this background and the intimate link between endothelial dysfunction and the pathogenesis of cardiovascular disease, it is consistent that reactive hyperemia can track disease progression and cardiovascular risk, as reviewed in the Introduction.

In most of the relevant studies, reactive hyperemia was evaluated in a single forearm, without specification of subject handedness. It makes sense that vascular responses in the skin should be symmetrical, as we indeed verified (Figures 1 and 2), but this assumption is less straightforward in the case of muscle. Carlson *et al.* (1987) examined 16 healthy subjects of both sexes with plethysmography and found a greater total excess blood flow on the right than on the left forearm ( $8.5\pm 1.4$  vs.  $6.8\pm 1.4$  ml/100 ml tissue,  $p=0.043$ ). In contrast, no

such difference was reported in a more ancient work (Patterson and Whelan 1955). In none of these two studies was handedness reported. Our results clearly indicate that muscular reactive hyperemia does not systematically differ between the dominant and non dominant forearm.

Available studies have consistently found that reactive hyperemia, as evaluated in the forearm with strain gauge plethysmography, was blunted by pharmacological inhibition of COX. In healthy volunteers, acute reductions in the peak response ranging from 20 to 30 % were reported following acute oral administration of indomethacin (1.25 mg/kg) (Kilbom and Wennmalm 1976, Nowak and Wennmalm 1979), ibuprofen (1.2 g) (Engelke *et al.* 1996), or acetylsalicylate (2x 30 mg/kg) (Carlsson *et al.* 1983). We essentially reproduced these findings, although the decrease of peak forearm muscle hyperemia observed with 1 g acetylsalicylate amounted to somewhat less (17 %, Fig. 4) than the 30 % reported by Carlson *et al.* (1983), who used a much larger dose of the same drug. Thus, the dose of acetylsalicylate chosen in the present study may not have been sufficient to exert a maximal effect on reactive hyperemia in forearm muscle. Nevertheless, we and others have previously shown that 1 g acetylsalicylate administered orally was able to completely abolish the prostanoid dependent vasodilation induced in the skin by local application of anodal current (Durand *et al.* 2002, Golay *et al.* 2004). In forearm skin, this dose of acetylsalicylate had no effect on peak reactive hyperemia but reduced its duration (Figures 3 and 4). This finding must be taken with some caution considering the limited number of subjects in Experiment 2. Nevertheless, it might reconcile apparently discordant results obtained by various authors who did not report the full time course of reactive hyperemia, as evaluated in forearm skin with laser Doppler flowmetry. Moppet *et al.* (2003) described that the peak response was unaffected by either ibuprofen (800 mg) or rofecoxib (25 mg), but provided no information on the later time course. By contrast, while not reporting on the peak response, Bingelli *et al.* (2003) found a 25 % reduction by acetylsalicylate (1 g) of postischemic skin blood flow measured after 30-60 s of reperfusion. Similarly, another study describing a depression of skin reactive hyperemia following administration of indomethacin in fact only reports the area under curve of the response (Bisgaard *et al.* 1986). In finger skin, indomethacin (1.5 mg/kg) reduced peak reactive hyperemia, which however was measured with

finger plethysmography rather than with laser Doppler flowmetry, such that the first 15 s of the response were missed. Finally, our previous report (Dalle-Ave *et al.* 2004) that acetylsalicylate did not affect skin reactive hyperemia may have been due to the lower dose used in that study (0.5 g) in comparison with the present one (1 g).

It is an inherent limitation of plethysmography that it cannot capture the first few seconds of reactive hyperemia, and therefore may miss the actual peak, as most likely occurred in the present study, considering that the apparent maximal blood flow always corresponded to the first data point, obtained between 6 and 9 s after the release of arterial occlusion (Figures 1 and 3). We therefore cannot infer the impact of acetylsalicylate treatment on the actual maximal post-ischemic muscle blood flow, and neither can any of the aforementioned studies. Whether this actual maximum is resistant to COX blockade, as appears to be the case for peak reactive hyperemia in the skin, could only be resolved by using another methodology for the measurement of muscle blood flow.

The mechanisms which underly the dependence of postischemic vasodilation on prostanoids remain incompletely defined. A non-exhaustive list of possibilities includes the hypoxic activation of phospholipase A<sub>2</sub> and consequent release of arachidonic acid from various cell types (Gross *et al.* 2005), the receptor-mediated stimulation of endothelial COX by the ADP accumulated in the course of ischemia (Boeynaems and Galland 1983), and the non-receptor-mediated stimulation of the same enzyme by hemodynamic forces acting during reperfusion (Koller and Kalley 1990a, Koller *et al.* 1994).

Reactive hyperemia elicited by 3 min of forearm ischemia consistently lasted much longer in skin than in muscle (Figures 1-4). To our knowledge, this fact has escaped attention so far, no other study having carried out, as was done here, the concomitant evaluation in both tissues of vascular responses to ischemia of identical durations. One – admittedly simplistic – explanation could be that the oxygen debt incurred with 3 min of interrupted blood flow is less intense in muscle than it is in skin, due to the presence of myoglobin-bound oxygen in the former.

In summary, our data show that forearm muscle and skin reactive hyperemia do not systematically differ between the dominant and non-dominant side, but may both be blunted by acetylsalicylate. Thus, if these

responses are to be used as surrogate endpoints in studies of cardiovascular disease, confounding by laterality of measurement need not be feared, but the possible influence of non-steroidal anti-inflammatory drugs must be taken into account. However, the latter restriction might not apply to the peak response in the skin.

### Conflict of Interest

There is no conflict of interest.

### Acknowledgements

The study was supported by departmental funds.

### References

- ANDERSSON HI, EJLERTSSON G, LEDEN I, SCHERSTEN B: Impact of chronic pain on health care seeking, self care, and medication. Results from a population-based Swedish study. *J Epidemiol Community Health* **53**: 503-509, 1999.
- BINGGELI C, SPIEKER LE, CORTI R, SUDANO I, STOJANOVIC V, HAYOZ D, LUSCHER TF, NOLL G: Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: a monitoring test of endothelial dysfunction for clinical practice? *J Am Coll Cardiol* **42**: 71-77, 2003.
- BISGAARD H, KRISTENSEN JK, SONDERGAARD J: A new technique for ranking vascular corticosteroid effects in humans using laser-Doppler velocimetry. *J Invest Dermatol* **86**: 275-278, 1986.
- BOEGLI Y, GREMION G, GOLAY S, KUBLI S, LIAUDET L, LEYVRAZ PF, WAEBER B, FEIHL F: Endurance training enhances vasodilation induced by nitric oxide in human skin. *J Invest Dermatol* **121**: 1197-1204, 2003.
- BOEYNAEMS JM, GALAND N: Stimulation of vascular prostacyclin synthesis by extracellular ADP and ATP. *Biochem Biophys Res Commun* **112**: 290-296, 1983.
- CARLSSON I, WENNMALM A: Effect of different prostaglandin synthesis inhibitors on post-occlusive blood flow in human forearm. *Prostaglandins* **26**: 241-252, 1983.
- CARLSSON I, LINDE B, WENNMALM A: Arachidonic acid metabolism and regulation of blood flow: effect of indomethacin on cutaneous and subcutaneous reactive hyperaemia in humans. *Clin Physiol* **3**: 365-373, 1983.
- CARLSSON I, SOLLEVI A, WENNMALM A: The role of myogenic relaxation, adenosine and prostaglandins in human forearm reactive hyperaemia. *J Physiol Lond* **389**: 147-161, 1987.
- COHN JN: Introduction to surrogate markers. *Circulation* **109** (Suppl IV): IV20-21, 2004.
- COHN JN, QUYYUMI AA, HOLLENBERG NK, JAMERSON KA: Surrogate markers for cardiovascular disease: functional markers. *Circulation* **109** (Suppl IV): IV31-46, 2004.
- DALLE-AVE A, KUBLI S, GOLAY S, DELACHAUX A, LIAUDET L, WAEBER B, F. F: Acetylcholine-induced vasodilation and reactive hyperemia are not affected by acute cyclo-oxygenase inhibition in human skin. *Microcirculation* **11**: 327-336, 2004.
- DURAND S, FROMY B, BOUYE P, SAUMET JL, ABRAHAM P: Vasodilatation in response to repeated anodal current application in the human skin relies on aspirin-sensitive mechanisms. *J Physiol Lond* **540**: 261-269, 2002.
- ENGELKE KA, HALLIWILL JR, PROCTOR DN, DIETZ NM, JOYNER MJ: Contribution of nitric oxide and prostaglandins to reactive hyperemia in human forearm. *J Appl Physiol* **81**: 1807-1814, 1996.
- GOLAY S, HAEBERLI C, DELACHAUX A, LIAUDET L, KUCERA P, WAEBER B, FEIHL F: Local heating of human skin causes hyperemia without mediation by muscarinic cholinergic receptors or prostanoids. *J Appl Physiol* **97**: 1781-1786, 2004.
- GROSS GJ, FALCK JR, GROSS ER, ISBELL M, MOORE J, NITHIPATIKOM K: Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. *Circ Res* **68**: 18-25, 2005.
- HIGASHI Y, SASAKI S, NAKAGAWA K, MATSUURA H, KAJIYAMA G, OSHIMA T: A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. *Am J Cardiol* **87**: 121-125, A129, 2001.
- HIROOKA Y, IMAIZUMI T, TAGAWA T, SHIRAMOTO M, ENDO T, ANDO S, TAKESHITA A: Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure. *Circulation* **90**: 658-668., 1994.

- ISHIBASHI Y, TAKAHASHI N, SHIMADA T, SUGAMORI T, SAKANE T, UMENO T, HIRANO Y, OYAKE N, MURAKAMI Y: Short duration of reactive hyperemia in the forearm of subjects with multiple cardiovascular risk factors. *Circ J* **70**: 115-123, 2006.
- KILBOM A, WENNMALM A: Endogenous prostaglandins as local regulators of blood flow in man: effect of indomethacin on reactive and functional hyperaemia. *J Physiol Lond* **257**: 109-121, 1976.
- KOLLER A, BAGI Z: On the role of mechanosensitive mechanisms eliciting reactive hyperemia. *Am J Physiol* **283**: H2250-H2259, 2002.
- KOLLER A, KALEY G: Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation. *Circ Res* **67**: 529-534, 1990a.
- KOLLER A, KALEY G: Role of endothelium in reactive dilation of skeletal muscle arterioles. *Am J Physiol* **259**: H1313-H1316, 1990b.
- KOLLER A, SUN D, HUANG A, KALEY G: Corelease of nitric oxide and prostaglandins mediates flow-dependent dilation of rat gracilis muscle arterioles. *Am J Physiol* **267**: H326-H332, 1994.
- KUBLI S, WAEBER B, DALLE-ÀVE A, FEIHL F: Reproducibility of laser-Doppler imaging of skin blood flow as a tool to assess endothelial function. *J Cardiovasc Pharmacol* **36**: 640-648, 2000.
- MANCINI GB, DAHLOF B, DIEZ J: Surrogate markers for cardiovascular disease: structural markers. *Circulation* **109** (Suppl IV): IV22-30, 2004.
- MOPPETT IK, DAVIES JA, MAHAJAN RP: Non-selective and cyclo-oxygenase-2-specific non-steroidal anti-inflammatory drugs impair the hyperaemic response of skin to brief axillary artery occlusion. *Br J Anaesth* **91**: 353-356, 2003.
- NOWAK J, WENNMALM A: A study on the role of endogenous prostaglandins in the development of exercise-induced and post-occlusive hyperemia in human limbs. *Acta Physiol Scand* **106**: 365-369, 1979.
- PATTERSON G, WHELAN RF: Reactive hyperemia in the human forearm. *Clin Sci* **14**: 197-211, 1955.
- PELLATON S, KUBLI S, FEIHL F, WAEBER B: Blunted vasodilatory responses in the cutaneous microcirculation of cigarette smokers. *Am Heart J* **144**: 269-274, 2002.
- SANADA M, HIGASHI Y, NAKAGAWA K, TSUDA M, KODAMA I, KIMURA M, CHAYAMA K, OHAMA K: Hormone replacement effects on endothelial function measured in the forearm resistance artery in normocholesterolemic and hypercholesterolemic postmenopausal women. *J Clin Endocrinol Metab* **87**: 4634-4641, 2002.
- ŠKRHA J, PRÁZNÝ M, HAAS T, KVASNIČKA J, KALVODOVÁ B: Comparison of laser-Doppler flowmetry with biochemical indicators of endothelial dysfunction related to early microangiopathy in Type 1 diabetic patients. *J Diabetes Complications* **15**: 234-240, 2001.
- TUR E, YOSIPOVITCH G, BAR-ON Y: Skin reactive hyperemia in diabetic patients. A study by laser Doppler flowmetry. *Diabetes Care* **14**: 958-962, 1991.
- VUILLEUMIER P, DECOSTERD D, MAILLARD M, BURNIER M, HAYOZ D: Postischemic forearm skin reactive hyperemia is related to cardiovascular risk factors in a healthy female population. *J Hypertens* **20**: 1753-1757, 2002.
- WILLIAMS B: Recent hypertension trials: implications and controversies. *J Am Coll Cardiol* **45**: 813-827, 2005.
- WU TC, CHEN YH, CHEN JW, CHEN LC, LIN SJ, DING PY, WANG SP, CHANG MS: Impaired forearm reactive hyperemia is related to late restenosis after coronary stenting. *Am J Cardiol* **85**: 1071-1076, 2000.